🇺🇸 Interferon beta-1a (Avonex) in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Abdominal Distension — 1 report (10%)
- Alopecia — 1 report (10%)
- Back Pain — 1 report (10%)
- Blood Pressure Decreased — 1 report (10%)
- Chest Pain — 1 report (10%)
- Diarrhoea — 1 report (10%)
- Dyspnoea — 1 report (10%)
- Ear Pain — 1 report (10%)
- Feeling Abnormal — 1 report (10%)
- Flushing — 1 report (10%)
Interferon beta-1a (Avonex) in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Interferon beta-1a (Avonex) approved in United States?
Interferon beta-1a (Avonex) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Interferon beta-1a (Avonex) in United States?
Biogen is the originator. The local marketing authorisation holder may differ — check the official source linked above.